GSK aims to file up to 20 new drugs for approval by 2020

The GlaxoSmithKline logo is seen at the entrance of a building in LuxembourgLONDON (Reuters) – GlaxoSmithKline said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair. Britain's biggest drugmaker is trying to boost low investor expectations for its product pipeline by hosting its first research and development day in more than a decade. The company highlighted advanced and early-stage projects in respiratory medicine, immunology, oncology, vaccines, HIV and other infections, and rare diseases. …



Sexual Health News Headlines – Yahoo! News